Skip to content

EBITDA margin at other companies

ResMed logo
ResMedRMD
38.2%+2.5pp
LivaNova logo
LivaNovaLIVN
16.8%+1.3pp
Globus Medical logo
Globus MedicalGMED
26.3%+5.6pp
Stryker logo
StrykerSYK
24.6%+4.7pp
ITG
Integer HoldingsITGR
18.3%-0.8pp
Medtronic logo
MedtronicMDT
25.9%-0.4pp

Other financials

Income statement

See full
Revenue$204.6M+1.6%
Gross profit$176.9M+3.7%
Operating income-$1.1M+24.7%
Net income-$11.3M-477%
EPS (diluted)-$0.39-490%

Balance sheet

See full
Cash & equivalents$98.9M+83.6%
Total debt$29.6M-11.8%
Total equity$792.3M+24.6%
Total assets$911.4M+24.7%

Cash flow

See full
Operating cash flow$12.8M+292%
CapEx$9.7M+15.7%
Free cash flow$3.1M+121%

Valuation

See full
Market cap$1.24B-67.8%
Enterprise value$1.18B-69.4%
P/E9.5×-48.6×
P/S1.4×-3.2×

Profitability

See full
Gross margin85.8%+1.1pp
Operating margin5.6%-0.3pp
Net margin14.3%+6.4pp
FCF margin10.6%+1.2pp

Returns & leverage

See full
Return on equity18.4%+7.5pp
Debt / equity0.0×
Current ratio6.3×-2.7×

Where this comes from

Calculated from Inspire Medical Systems’s reported figures.

Based on trailing twelve months.

The official record: Inspire Medical Systems’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inspire Medical Systems's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inspire Medical Systems's EBITDA margin?
Inspire Medical Systems (INSP) reported EBITDA margin of 7.4% in Q1 2026.
How has Inspire Medical Systems's EBITDA margin changed year-over-year?
Inspire Medical Systems's EBITDA margin increased by 5.5% year-over-year, from 7% to 7.4%.
What is the long-term trend for Inspire Medical Systems's EBITDA margin?
Over 4 years (2020 to 2025), Inspire Medical Systems's EBITDA margin has grown at a -37.9% compound annual growth rate (CAGR), from -48% to 7.1%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.